NEXI...this my concern...is it smoke or what? On January 18, 2024, NexImmune, Inc. (the “Company”) reconvened its special meeting of stockholders for the purpose of approving the liquidation and dissolution of the Company and the Plan of Liquidation and Dissolution (the “Special Meeting”). There were 331,696 shares of common stock present or represented by proxy at the Special Meeting, which did not constitute a quorum under the Company’s Amended and Restated Bylaws.
Accordingly, the Special Meeting was further adjourned without any business being conducted in order to allow time to achieve a quorum and to allow the Company’s stockholders additional time to vote on the proposals set forth in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 20, 2023 (the “Proxy Statement”).
The adjourned Special Meeting is scheduled to reconvene on Wednesday, February 7, 2024 at 10:00 a.m., Eastern Time in a virtual format. The close of business on November 6, 2023 will continue to be the record date for the determination of stockholders of the Company entitled to vote at the Special Meeting. Stockholders of the Company who have previously submitted their proxy or otherwise voted do not need to take any action.
No changes have been made in the proposals to be voted on by stockholders at the Special Meeting. The Company encourages all of its stockholders to read the Proxy Statement, which is available free of charge on the SEC website at www.sec.gov.
During the period of adjournment, the Company will continue to solicit votes from its stockholders with respect to the proposals set forth in the Proxy Statement. The Company encourages all stockholders who have not yet voted to do so promptly. The Company expects that its existing cash and cash equivalents will be sufficient to meet its anticipated cash requirements through mid-February 2024. In addition to soliciting the votes as described, the Company will continue exploring strategic or financing alternatives to advance the science. As of November 6, 2023, the Company had 1,058,125 shares of common stock issued and outstanding